Vertex Pharmaceuticals (VRTX)

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook.

The company seems to be doing everything it's supposed to be doing; the stock just isn't responding.

The market is underestimating these companies' long-term prospects.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade...

Are there significant gains ahead for one (or both) of these innovative biotechs?

The biotech's innovative platform could pay off.

Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi...

The market wasn't impressed by its latest quarterly update.

Vertex (VRTX) Q1 2026 Earnings Call Transcript

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the market close on Monday.

Vertex (VRTX) Q2 2025 Earnings Call Transcript

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know. Vertex Pharmace...

These longtime market beaters may not have peaked yet.

They may suffer the occasional knee-jerk setback. By and large, though, investors understand these companies are capable of standing up to almost any challenge.

These companies are leaders in their fields.

The biotech's candidate may treat a great number of illnesses that have one thing in common.

This particular player has seen its yield rise in recent years.

These stocks come with risk, but they also have some exciting long-term growth opportunities.